[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oswaldo Cruz Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":115},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637980","improving-access-to-prep-hiv-prevention-medication-for-people-in-underserved-areas-of-rio-de-janeiro-100637980",false,"NCT07584122","Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro","Bringing PrEP to Underserved Communities in Rio de Janeiro: the PrEPOUT Rio Study","Inclusion Criteria:\n\n* Individuals aged 15 years or older\n* Gay, bisexual, and other men who have sex with men (MSM)\n* Transgender women and travestis\n* Other sexual and gender minorities (SGM)\n* Cisgender women in situations of social or economic vulnerability\n* Sex workers\n* Individuals seeking HIV testing and\u002For pre-exposure prophylaxis (PrEP)\n* HIV-negative at screening\n* Willing and interested in initiating PrEP\n* Eligible for PrEP according to Brazilian national guidelines\n\nExclusion Criteria:\n\n* Positive HIV test result at screening or during study participation\n* Individuals not eligible for PrEP according to Brazilian national guidelines",true,"ALL","15 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to improve access to HIV prevention using pre-exposure prophylaxis (PrEP) among underserved populations in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. Despite the proven effectiveness of PrEP, many people at higher risk of HIV face barriers to accessing and continuing this prevention method, especially those living in socially and economically vulnerable communities.\n\nThe study will evaluate whether offering PrEP directly in community-based settings-such as non-governmental organizations, mobile health units, and through telehealth and digital tools-can increase its uptake and continued use. Participants who test negative for HIV will be offered daily oral PrEP, along with counseling and follow-up support. Those who test positive will be referred for appropriate treatment.\n\nThe main hypothesis is that delivering PrEP in community settings, combined with supportive strategies like mobile health interventions, will be feasible, acceptable, and more effective in reaching and engaging vulnerable populations, ultimately helping to reduce new HIV infections.",[27],"HIV Infections","RECRUITING","2026-05-06",{"date":31,"type":32},"2026-05-13","ACTUAL",{"date":34,"type":32},"2025-09-01",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Oswaldo Cruz Foundation","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100631418","doxi-rio-study-on-the-use-of-doxycycline-to-prevent-sexually-transmitted-infections-in-rio-de-janeiro-100631418","NCT07500415","Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro","Doxi-Rio: Pilot Implementation of Post-exposure Prophylaxis for Sexually Transmitted Infections With Doxycycline in Rio de Janeiro, Brazil","Inclusion Criteria:\n\n* Individuals assigned male at birth (cisgender or transgender men), transgender women, or travestis who have sex with men\n* Age ≥18 years\n* Living with HIV or currently using HIV pre-exposure prophylaxis (PrEP) for at least 6 months\n* History of at least one bacterial sexually transmitted infection (chlamydia, gonorrhea, or syphilis) in the past 12 months (laboratory-confirmed or self-reported)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to doxycycline or other tetracycline-class antibiotics\n* Current use of medications that may significantly interact with doxycycline or are contraindicated, including systemic retinoids, barbiturates, carbamazepine, or phenytoin","18 Years",{"count":50,"type":21},200,[24],"The goal of this clinical trial is to learn if doxycycline post-exposure prophylaxis (doxy-PEP) can help prevent bacterial sexually transmitted infections (STIs) among sexual and gender minorities in Rio de Janeiro, Brazil, including men who have sex with men, transgender women, and travestis who are living with HIV or using HIV pre-exposure prophylaxis (PrEP). Bacterial STIs such as syphilis, gonorrhea, and chlamydia remain common in these populations, even with existing prevention strategies.\n\nThis study aims to answer the following questions: whether doxy-PEP can reduce the number of new STIs, whether it is safe and well tolerated, whether participants use it as recommended, and whether its use may contribute to antibiotic resistance or changes in the body's natural bacteria. Doxy-PEP involves taking a dose of doxycycline, an antibiotic, shortly after sexual activity to reduce the risk of acquiring STIs.\n\nParticipants will first receive information and counseling about doxy-PEP, including its possible benefits and risks, and will then choose whether or not to use this prevention strategy. Those who choose to use doxy-PEP will take doxycycline after sex as instructed and will be followed for up to 48 weeks, with clinic visits approximately every three months. During these visits, participants will be tested for STIs, monitored for side effects, and asked about medication use, sexual health, and overall well-being.\n\nResearchers will collect information on new STI diagnoses, safety, and how consistently participants use doxy-PEP. The study will also explore participants' experiences and perceptions of this strategy. The results of this study will help determine whether doxy-PEP is a practical and acceptable approach for STI prevention in Brazil and may inform future public health strategies.",[54,55,56,57,27],"Sexually Transmitted Diseases","Syphilis","Gonorrhea","Chlamydia Infections","2026-03-24",{"date":60,"type":32},"2026-03-30",{"date":62,"type":32},"2025-10-28",{"date":64,"type":21},"2028-05",{"name":38,"class":39},1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100631201","imprep-len-brasil-twice-yearly-lenacapavir-for-hiv-prevention-100631201","NCT07497594","ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","Expanding PrEP Options Among Young MSM, Transgender and Non-binary Persons in Brazil: Incorporating Twice-yearly Lenacapavir for HIV Prevention - The ImPrEP LEN Brasil Study","ImPrEP LEN","Inclusion Criteria:\n\nAbility to understand and sign the Informed Consent Form, which must be obtained before the initiation of any study procedures, and willingness to comply with the protocol requirements\n\nBe a cisgender man, a non-binary person designated male at birth, or a transgender woman or transgender man\n\nReport having engaged in anal sex with a person designated male at birth within the last six months\n\nBe between 16 and 30 years of age\n\nHave a body weight equal to or greater than 35 kilograms\n\nSeek care at a participating study clinic for human immunodeficiency virus testing or initiation of human immunodeficiency virus pre-exposure prophylaxis, either spontaneously or through peer invitation\n\nHave a non-reactive result on a rapid test for human immunodeficiency virus\n\nBe an individual without prior use of human immunodeficiency virus pre-exposure prophylaxis, or an individual with prior use who remains in a situation of vulnerability, characterized by:\n\na history of oral human immunodeficiency virus pre-exposure prophylaxis with at least two prior dispensations without return for a new pickup in the six months preceding the enrollment visit, or\n\na history of long-acting cabotegravir use with a delay of at least one scheduled reload dose\n\nExclusion Criteria:\n\nKnown hypersensitivity to the study medication, its metabolites, or formulation excipients\n\nSevere hepatic impairment or a history or current clinical condition of decompensated liver cirrhosis, such as ascites, encephalopathy, or variceal bleeding\n\nKnown or suspected severe active infection, such as active tuberculosis\n\nNeed for continuous use of contraindicated concomitant medications\n\nAny clinical or psychosocial condition, or prior treatment, that in the opinion of the investigator makes the participant unsuitable for the study or unable to comply with dosing requirements\n\nConfirmed or suspected infection with the human immunodeficiency virus\n\nPlans to move outside the study area during the follow-up period\n\nPrior participation in a clinical study using Lenacapavir in the PURPOSE study\n\nPrior participation in a human immunodeficiency virus vaccine study, except in cases where the participant provides documentation demonstrating receipt of placebo and not the active product\n\nCurrent participation in another interventional human immunodeficiency virus prevention study that, in the opinion of the investigator, may interfere with the conduct of this study","16 Years","30 Years",{"count":78,"type":21},1500,[24],"The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this option compared to daily oral pre- exposure prophylaxis (PrEP). The main questions it aims to answer are:\n\nHow many participants get HIV while using long-acting lenacapavir? How safe is long-acting lenacapavir in real-world health services? How many participants continue using their chosen prevention method over time? What factors help or make it harder for participants to stay on prevention? Researchers will compare two HIV prevention options to understand how they work in routine care: Long-acting lenacapavir, given as an injection under the skin every 6 months, Daily oral pre-exposure prophylaxis (PrEP), taken as a pill containing tenofovir disoproxil fumarate and emtricitabine, Participants will choose the prevention option they prefer after receiving counseling. This is not a randomized study. Researchers will follow participants for up to 2 years. Participants will: Receive either an injection every 6 months or take a daily pill, Visit the clinic regularly for HIV testing and health checkups, Receive testing and treatment for sexually transmitted infections, Answer questions about their health, medication use, and experiences, Receive prevention counseling and condoms. This study will help health services understand how to offer long-acting HIV prevention in Brazil and how to better support people who want to prevent HIV infection.",[82],"Contact With or Exposure to Human Immunodeficiency Virus",{"date":84,"type":32},"2026-03-27",{"date":86,"type":32},"2026-02-03",{"date":88,"type":21},"2029-09",{"name":38,"class":39},8,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":66},"100295929","phase-4-immunogenicity-and-safety-of-the-yellow-fever-vaccine-in-hiv-infected-individuals-100295929","NCT03132311","Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals","YF-HIV","Inclusion Criteria:\n\n* HIV infected adults, age \\>= 18 and \\\u003C60 years old.\n* CD4 \\> 200 cells\u002Fmm³ within the last 6 months prior to inclusion. Individuals with no CD4 results in the last 6 months which have undetectable HIV viral load and last CD4 count \\> 350 can be included.\n* Healthy HIV-uninfected individuals (aged \\>= 18 and \\\u003C 60)\n* No history of Yellow Fever vaccination\n* Willing to participate and to sign the consent\n\nExclusion Criteria:\n\n* Individuals with chronic diseases such as: decompensated diabetes, kidney failure (in dialysis), liver failure\u002Fcirrhosis, cancer (except for non-melanoma skin cancer and in situ HIV related carcinoma), use of immunosuppressive agents (including prednisone ≥ 20mg\u002Fday, during 7 or more days in the last 30 days before inclusion).\n* Pregnant women\n* Hypersensitivity reaction to eggs, chicken protein. Allergy to erythomycin or kanamycin. Hereditary fructose intolerance.\n* Administration of immunoglobulins or blood derivates \\\u003C 3 months or life attenuated vaccine \\\u003C1 month.\n* History of thymic dysfunction (including thymoma and thymectomy).\n* Use of anti-CCR5\n* symptoms of severe acute illnesses or fever (axillary temperature ≥ 38°C)\n* HIV positive rapid test for HIV negative subjects.","59 Years",{"count":20,"type":21},[101],"PHASE4","Phase 4 study to evaluate the immunogenicity and Safety of the 17DD Yellow Fever vaccine in HIV infected individuals, compared to non-HIV-infected individuals.\n\nMain objective:\n\nTo compare the proportion of seroconversion and the geometric mean of neutralizing antibodies 30 days and 365 days after vaccine.\n\nSecondary objectives:\n\nTo evaluate whether the titles of neutralizing antibodies are associated with CD4 lymphocyte counts, CD8 lymphocyte counts, CD4 nadir, HIV viral load and use of antiretroviral therapy. To assess the yellow fever vaccine viremia at day 10 after vaccine.To compare the incidence of adverse events in HIV-infected and non-HIV-infected individuals.",[27],[105,106],"yellow fever vaccine","hiv","2018-07-27",{"date":109,"type":32},"2018-07-30",{"date":111,"type":32},"2017-05-29",{"date":113,"type":21},"2028-12",{"name":38,"class":39},""]